Tonix Pharmaceuticals Gets U.S. Patents for Smallpox, Monkeypox Vaccine
marketwatch.com
news
2022-06-01 11:21:00

By Chris Wack The U.S. Patent and Trademark Office issued Tonix Pharmaceuticals Holding Corp. a U.S. patent on Tuesday for TNX-801 smallpox and monkeypox vaccine and recombinant pox virus platform technology, the company said Wednesday. This patent, entitled "Synthetic Chimeric Poxviruses," includes claims covering synthetic horsepox virus, the basis for the TNX-801 vaccine against other pathogens, including SARS-CoV-2, Tonix said. The patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.
